LT2822947T - Tlr7 agonisto arginino druskos - Google Patents

Tlr7 agonisto arginino druskos

Info

Publication number
LT2822947T
LT2822947T LTEP13708142.8T LT13708142T LT2822947T LT 2822947 T LT2822947 T LT 2822947T LT 13708142 T LT13708142 T LT 13708142T LT 2822947 T LT2822947 T LT 2822947T
Authority
LT
Lithuania
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
LTEP13708142.8T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha JAIN
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of LT2822947T publication Critical patent/LT2822947T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LTEP13708142.8T 2012-03-07 2013-03-07 Tlr7 agonisto arginino druskos LT2822947T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
LT2822947T true LT2822947T (lt) 2016-10-10

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13708142.8T LT2822947T (lt) 2012-03-07 2013-03-07 Tlr7 agonisto arginino druskos

Country Status (18)

Country Link
US (1) US9320748B2 (lt)
EP (1) EP2822947B1 (lt)
JP (1) JP6325986B2 (lt)
CN (1) CN104203946B (lt)
AU (1) AU2013229466A1 (lt)
CA (1) CA2865759C (lt)
CY (1) CY1118091T1 (lt)
DK (1) DK2822947T3 (lt)
ES (1) ES2597755T3 (lt)
HR (1) HRP20161354T1 (lt)
HU (1) HUE030175T2 (lt)
LT (1) LT2822947T (lt)
MX (1) MX346678B (lt)
PL (1) PL2822947T3 (lt)
PT (1) PT2822947T (lt)
RU (1) RU2014140336A (lt)
SI (1) SI2822947T1 (lt)
WO (1) WO2013131985A1 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CA2810011A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
DK3122378T3 (da) 2014-03-26 2020-03-02 Glaxosmithkline Biologicals Sa Mutante stafylokokantigener
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
EP0769018B1 (en) 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteins and vaccines
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP2335724A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
EP1729800A4 (en) 2004-03-02 2008-06-11 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008544745A (ja) 2005-05-12 2008-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2006341122B2 (en) 2005-12-22 2013-08-22 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
WO2010140119A1 (en) 2009-06-01 2010-12-09 Novartis Ag COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
JP5867952B2 (ja) * 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CA2810011A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
ES2612511T3 (es) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Nanoemulsiones de adyuvante con inhibidores de cristalización
EP2763695A1 (en) * 2011-09-01 2014-08-13 Novartis AG Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
JP6325986B2 (ja) 2018-05-16
US20150125475A1 (en) 2015-05-07
WO2013131985A1 (en) 2013-09-12
MX346678B (es) 2017-03-29
DK2822947T3 (en) 2016-09-19
ES2597755T3 (es) 2017-01-20
HUE030175T2 (en) 2017-04-28
SI2822947T1 (sl) 2016-10-28
AU2013229466A1 (en) 2014-09-04
RU2014140336A (ru) 2016-04-27
EP2822947A1 (en) 2015-01-14
CY1118091T1 (el) 2017-06-28
CA2865759C (en) 2020-07-21
CA2865759A1 (en) 2013-09-12
CN104203946A (zh) 2014-12-10
HRP20161354T1 (hr) 2016-12-02
US9320748B2 (en) 2016-04-26
PL2822947T3 (pl) 2017-01-31
JP2015511957A (ja) 2015-04-23
PT2822947T (pt) 2016-09-26
EP2822947B1 (en) 2016-08-03
MX2014010423A (es) 2014-09-22
CN104203946B (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
PT2822947T (pt) Sais de arginina de um agonista de tlr7
IL231269B (en) Preparations for the treatment of HIV
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
HK1192562A1 (zh) 取代的苯甲酰胺衍生物
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
EP2785766A4 (en) HYDROXYPOLYAMINSALZE
HK1200454A1 (zh) 琥珀酸鹽的晶形
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
HRP20171362T1 (hr) Soli benzotiazolonskog spoja koje služe kao agonist beta-2-adrenoceptora
PL2760822T3 (pl) Sole desfezoterodyny
EP2702991A4 (en) COMPOSITION OF ENTACOPONE
ZA201308872B (en) Use of a dinitromethane salt
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201100332D0 (en) Monty Izofit
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201219868D0 (en) Facilitating completion of a form
GB201204590D0 (en) Prodrugs of thiazolamine compounds